Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

PURPOSE: Severe eosinophilic asthma (SEA) is characterized by high eosinophilia, severe symptoms, important comorbidities, frequent exacerbations, and poor asthma control. Benralizumab, targeting the interleukin-5 receptor alpha, proved effective in inducing rapid eosinophil depletion and ameliorati...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzella, Francesco, Bonavia, Marco, Bonini, Matteo, D’Amato, Maria, Lombardo, Salvatore, Murgia, Nicola, Patella, Vincenzo, Triggiani, Massimo, Pelaia, Girolamo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910093/
https://www.ncbi.nlm.nih.gov/pubmed/33654412
http://dx.doi.org/10.2147/JAA.S295676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910093/
https://www.ncbi.nlm.nih.gov/pubmed/33654412
http://dx.doi.org/10.2147/JAA.S295676

Ejemplares similares